mass spectrometry raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-31 and is reviewed periodically as new material appears.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
| Property | Value | Notes |
|---|---|---|
| Appearance as powder | White to off-white solid | Minor batch-to-batch variation is normal |
| Solubility class | Soluble in water and aqueous buffers | Dissolution can be slowed by aggregates |
| Typical storage temperature | Minus 20 degrees Celsius or below | Protected from light and moisture |
| Storage after reconstitution | 2 to 8 degrees Celsius, short term | Longer holding requires freezing |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity and identity confirmation |
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
The relevant timescale is, to some degree, arbitrarily defined: 1000 seconds is sometimes employed, as this is regarded as the lower limit for the amount of time required for chemical or chromatographic separation of enantiomers in a practical sense. Molecules that are chiral at room temperature due to restricted rotation about a single bond (barrier to rotation ≥ ca. 23 kcal/mol) are said to exhibit atropisomerism. A chiral compound can contain no improper axis of rotation (Sn), which includes planes of symmetry and inversion center. Chiral molecules are always dissymmetric (lacking Sn) but not always asymmetric (lacking all symmetry elements except the trivial identity). Asymmetric molecules are always chiral. The following table shows some examples of chiral and achiral molecules, with the Schoenflies notation of the point group of the molecule. In the achiral molecules, X and Y (with no subscript) represent achiral groups, whereas XR and XS or YR and YS represent enantiomers. Note that there is no meaning to the orientation of an S2 axis, which is just an inversion. Any orientation will do, so long as it passes through the center of inversion. Also note that higher symmetries of chiral and achiral molecules also exist, and symmetries that do not include those in the table, such as the chiral C3 or the achiral S4.
=== Biological agents === All six of the elements commonly recognised as metalloids have toxic, dietary or medicinal properties. Arsenic and antimony compounds are especially toxic; boron, silicon, and possibly arsenic, are essential trace elements. Boron, silicon, arsenic, and antimony have medical applications, and germanium and tellurium are thought to have potential. Boron is used in insecticides and herbicides. It is an essential trace element. As boric acid, it has antiseptic, antifungal, and antiviral properties. Silicon is present in silatrane, a highly toxic rodenticide. Long-term inhalation of silica dust causes silicosis, a fatal disease of the lungs. Silicon is an essential trace element. Silicone gel can be applied to badly burned patients to reduce scarring. Salts of germanium are potentially harmful to humans and animals if ingested on a prolonged basis. There is interest in the pharmacological actions of germanium compounds but no licensed medicine as yet. Arsenic is notoriously poisonous and may also be an essential element in ultratrace amounts. During World War I, both sides used "arsenic-based sneezing and vomiting agents ... to force enemy soldiers to remove their gas masks before firing mustard or phosgene at them in a second salvo". It has been used as a pharmaceutical agent since antiquity, including for the treatment of syphilis before the development of antibiotics. Arsenic is also a component of melarsoprol, a medicinal drug used in the treatment of human African trypanosomiasis or sleeping sickness.
Dinosaurs have been widely depicted in culture since the English palaeontologist Richard Owen coined the name dinosaur in 1842. As soon as 1854, the Crystal Palace Dinosaurs were on display to the public in south London. One dinosaur appeared in literature even earlier, as Charles Dickens placed a Megalosaurus in the first chapter of his novel Bleak House in 1852. The dinosaurs featured in books, films, television programs, artwork, and other media have been used for both education and entertainment. The depictions range from the realistic, as in the television documentaries of the 1990s and first decade of the 21st century, to the fantastic, as in the monster movies of the 1950s and 1960s. The snake or serpent has played a powerful symbolic role in different cultures. In Egyptian history, the Nile cobra adorned the crown of the pharaoh. It was worshipped as one of the gods and was also used for sinister purposes: murder of an adversary and ritual suicide (Cleopatra). In Greek mythology, snakes are associated with deadly antagonists, as a chthonic symbol, roughly translated as earthbound. The nine-headed Lernaean Hydra that Hercules defeated and the three Gorgon sisters are children of Gaia, the earth. Medusa was one of the three Gorgon sisters who Perseus defeated. Medusa is described as a hideous mortal, with snakes instead of hair and the power to turn men to stone with her gaze. After killing her, Perseus gave her head to Athena who fixed it to her shield called the Aegis.
Sources: en.wikipedia.org
In 2017, to coincide with the opening of Little Caesars Arena, the company launched a slightly updated logo, which removed Caesar's chest hair, updated the wreath, and updated the toga to have hidden letters spelling "LC" for "Little Caesars". The company also started using the updated Caesar in its advertising, replacing the more cartoonish Caesar that had been used in ads since 1988.
== SE == se – (s) Northern Sami language (ISO 639-1 code) Se – (s) Selenium SE (s) Seychelles (FIPS 10-4 country code) (i) Societas Europaea (form of business organization in the EU) South-east (s) Sweden (ISO 3166 digram) (i) Synthetic Environment Systems engineering SEAD – (i) Suppression of Enemy Air Defence(s) SEADI – (i) Senior Executioner of Approved Driving Instructors SEAFDEC – (p) Southeast Asian Fisheries Development Center SEAL – (p) SEa-Air-Land SEAT – (a) Sociedad Española de Automóviles de Turismo (Spanish for "Spanish Touring Car Company") SEATO – (a) Southeast Asia Treaty Organization SeaWiFS – (p) Sea-Viewing Wide Field of View Sensor (satellite instrument) SEC (i) U.S. Securities and Exchange Commission (p) Security Southeastern Conference SECaaS - (p) Security-as-a-Service SECAM – (a) Séquentiel couleur à mémoire (French for "Colour Sequential with Memory"; TV standard, cf. NTSC, PAL) SECDEF – (p) (U.S.) Secretary of Defense SED – (i) CERDEC Software Engineering Directorate SEDRIS – (a) Synthetic Environment Data Representation and Interchange Specification SEE – (a) Small Emplacement Excavator SEG – (i) Society of Exploration Geophysicists SEG – (i) Special Escort Group SEK – (s) Swedish krona (ISO 4217 currency code) Selkent – (p) South East London & Kent Bus Company SELT – (a) Single Ended Line Test (ing) SEM (i/a) Sensor Employment Manager Switch to Email Mode, i.e.
== Diagnosis == SJIA is diagnosed clinically and corroborated by typical test findings; it is a diagnosis of exclusion. Other causes of fever, such as infections, cancer, and other inflammatory/rheumatologic disorders such autoinflamatory syndromes, systemic lupus erythematosus, and Kawasaki disease, must be ruled out. When a child is suspected of having sJIA, they should always have a full evaluation for infection and cancer. This evaluation should include blood and urine cultures, imaging tests, and perhaps a bone marrow exam or lymph node biopsy to rule out leukemia or lymphoma. According to the most recent International League of Associations for Rheumatology (ILAR) criteria, a child must have arthritis, ≥2 weeks of daily fever that is documented as occurring daily for ≥3 days, and any one of the following symptoms to be classified as having sJIA: organomegaly, lymphadenopathy, serositis, or non-fixed/evanescent rash While there are typical patterns of laboratory abnormalities, such as elevated C-reactive protein levels, high erythrocyte sedimentation rates, neutrophilia, thrombocytosis, and microcytic anemia, there are no particular laboratory tests for sJIA.
Sources: en.wikipedia.org
Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.
Hydrolysis, oxidation of susceptible residues, and aggregation all contribute, and their rates depend on pH, temperature, and concentration. Dissolved oxygen and trace metal ions accelerate oxidation. Keeping solutions cold, dilute, and free of unnecessary handling reduces these pathways.
Not always, because the value depends on the detection wavelength, the gradient, and how peak areas are integrated. A figure of ninety-eight percent from one laboratory may not mean the same as the same number from another. Comparing full chromatograms and mass spectra is more informative than comparing a single number.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.